CGTLive’s Weekly Rewind – September 9, 2022
Review top news and interview highlights from the week ending September 9, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. CAR T/CARVac Therapy Yields Responses in Refractory Testicular Cancer
BNT211 showed encouraging responses in testicular cancer but less encouraging responses in ovarian cancer.
2. Sequential T-Cell Redirection Therapies Yield Deep, Durable Responses in R/R Multiple Myeloma
Patients receiving CAR T-cell therapy or bispecific antibody therapies as first salvage therapy had an ORR of 84%.
3. Mark Forman, MD, PhD, on Genetic Testing and Further Research in Frontotemporal Dementia
The chief medical officer of Passage Bio discussed research needs in FTD.
4. Polycythemia Vera mRNA Therapy Receives FDA Fast Track Designation
SLN124 was well-tolerated in a previous clinical trial involving healthy volunteers.
5. Ornithine Transcarbamylase Gene Editing Program Nabs Another FDA Designation
iECURE is planning to submit an IND for GTP-506 in mid-2023.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Jeffrey Chamberlain, PhD, on the Import of Early Intervention in DMD
July 10th 2025The McCaw Endowed Chair of Muscular Dystrophy at University of Washington, discussed how comprehensive care for DMD patients involves early diagnosis, steroid treatment, consideration of mutation-specific therapies, and more.
